#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: U.S. National Stage Application of: Denton et al.

U.S. Application No.: 09/889,866
International Application No.: PCT/US00/22175
Atty. Docket No.: MWH-008US
International Application Filing: Date:August 11, 2000

For: Drug Target Isogenes: Polymorphisms in the Immunoglobulin E Receptor Beta Chain Gene

Assistant Commissioner for Patents
Patent and Trademark Office
Washington, D.C. 20231-0001

TRANSMITTAL

In response to the Notification of Defective Response under 35 U.S.C. 371 in the United States Elected Office (EO/US) dated February 14, 2002, enclosed herewith please find:

1. Response to Notification of Defective Response and Correction of First Named Applicant
2. A Combined Declaration and Power of Attorney for all named inventors (executed in counterpart) (4 pages)
3. Computer readable form (CRF) of the sequence listing.
4. Substitute Sequence Listing (26 pages)
5. An amendment directing entry of the substitute sequence listing into the specification
6. A Statement that "Sequence Listing" and CRF are the same and/or that papers submitted include no new matter
7. A copy of the above-identified Notice
8. A return receipt postcard

CERTIFICATION UNDER 37 C.F.R. SECTION 1.10*
*(Express Mail label number is **mandatory**.)*
(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on March 14, 2002 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EL594594785US addressed to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

Cathy Wilcox
(type or print name of person mailing paper)

Cathy Wilcox
Signature of person mailing

9 Fees

Surcharge fee set forth in 37 C.F.R. section 1.492(e) for accepting the Combined Declaration and Power of Attorney later than 30 months after the priority date in filing an application in the U.S. as an elected office is $130.00.

10. Fee payment

Fee payment in the amount of $130.00 is being made at this time.

11. Method of fee payment

Charge Account No. 50-1293, in the amount of $130.00. Please charge Account No. 50-1293 for any fee deficiency. A duplicate of this Cover Sheet is attached.

Date: 14-March-2002
Reg. No. 47,934
Tel. No. 203-786-3468

Sandra L. Shaner
Sandra L. Shaner
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: U.S. National Stage Application of: Denton et al.

U.S. Application No.: 09/889,866
International Application No.: PCT/US00/22175
Atty. Docket No.: MWH-008US
International Application Filing Date: August 11, 2000

For: Drug Target Isogenes: Polymorphisms in the Immunoglobulin E Receptor Beta Chain Gene

Box PCT
Assistant Commissioner for Patents
Patent and Trademark Office
Washington, D.C. 20231-0001

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE
AND CORRECTION OF FIRST NAMED APPLICANT
IN THE UNITED STATES ELECTED OFFICE (EO/US)

On February 14, 2002, the above-referenced Notification of Defective Response was mailed to Applicants indicating that the oath or declaration of the inventors needs to be furnished. Enclosed herewith is a Combined Declaration and Power of Attorney in compliance with 37 CFR 1.497(a) and (b), executed in counterpart by all named inventors.

The Notification also indicated that Applicants need to furnish the nucleotide and/or amino acid sequence disclosure. Enclosed herewith is a paper copy of the substitute sequence listing along with a computer readable form (CRF). An amendment directing its entry into the specification is also included herein.

Applicants would also like to note the First Named Applicant, Taieb Akremi, printed on the Notification is incorrect and should be changed to reflect Applicants' first named inventor, R. Rex Denton.

Applicants believe that this submission completes the requirements for acceptance under 35 U.S.C. 371 and acceptance is respectfully requested. Should any questions arise, or if Applicants or Applicants' Agent can facilitate examination of this application, it is

respectfully requested that the undersigned Agent be contacted so that any remaining issues can be resolved.

Date: 14 - March - 2002
Reg. No. 47,934
Tel. No. 203-786-3468

Sandra L. Shaner
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/889,866	Taieb Akremi	MWH-008US

INTERNATIONAL APPLICATION NO	
PCT/US00/22175	
I.A. FILING DATE	PRIORITY DATE
08/11/2000	08/24/1999

Inna Shtivelband
Genaissance Pharmaceuticals
5th Science Park
New Haven, CT 06511

CONFIRMATION NO. 5719

371 FORMALITIES LETTER

Date Mailed: 02/14/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- See Attachment(Raw Sequence Listing Error report)
- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

  - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

PATRICIA A BOOKER

Telephone: (703) 305-3738

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/889,866	PCT/US00/22175	MWH-008US

FORM PCT/DO/EO/916 (371 Formalities Notice)